Orchid Pharma Ltd

Orchid Pharma has faced significant volatility, reaching a new 52-week low and experiencing a 35.05% drop over the past four days. The stock has consistently underperformed against key moving averages and has declined 25.81% over the past year, contrasting with the Sensex's gains.

Orchid Pharma has faced notable stock volatility, with a significant decline on February 17, 2025, following a three-day losing streak that resulted in a cumulative loss of over 30%. The stock has dropped 46.30% in the past month and is trading below multiple moving averages, indicating ongoing challenges.

Orchid Pharma has faced notable volatility, hitting a new 52-week low and experiencing a significant decline over the past three days. The stock has consistently traded below key moving averages and recorded high intraday fluctuations, reflecting its struggles in a competitive market, contrasting with broader market gains.

Orchid Pharma has faced considerable stock volatility, experiencing a decline of 19.26% over a short period. The stock reached an intraday low of Rs 1001.05 and has fallen 40.23% in the past month, significantly underperforming compared to the broader market. It is trading below multiple moving averages.

Orchid Pharma's stock faced notable volatility on February 13, 2025, declining significantly and underperforming its sector. The stock opened lower and hit an intraday low, with heightened market fluctuations reflected in its volatility metrics. Over the past month, it has experienced a substantial drop compared to the stable performance of the Sensex.

Orchid Pharma has announced its financial results for the quarter ending December 2024, revealing a significant shift in performance metrics. The company's score has adjusted notably, indicating changes in its financial dynamics. Stakeholders are encouraged to monitor the evolving pharmaceutical sector and Orchid's strategic responses.

Orchid Pharma's stock has faced significant challenges, declining 5.0% on February 10, 2025, and accumulating an 11.21% drop over two days. The stock is trading below multiple moving averages, reflecting a bearish trend, and has seen a 27.42% decrease over the past month, contrasting with the Sensex's stability.

Orchid Pharma, a midcap pharmaceutical company, saw a significant decline on February 7, 2025, following a four-day gain streak. The stock underperformed its sector and reached an intraday low, indicating mixed momentum. Over the past month, it has faced substantial challenges, contrasting sharply with broader market trends.

Orchid Pharma, a midcap pharmaceutical company, saw a significant decline on February 7, 2025, following a four-day gain streak. The stock underperformed its sector and reached an intraday low, indicating mixed momentum. Over the past month, it has faced substantial challenges, contrasting sharply with broader market trends.

Orchid Pharma, a midcap pharmaceutical company, saw a significant decline on February 7, 2025, following a four-day gain streak. The stock underperformed its sector and reached an intraday low, indicating mixed momentum. Over the past month, it has faced substantial challenges, contrasting sharply with broader market trends.

Orchid Pharma, a midcap pharmaceutical company, saw a significant decline on February 7, 2025, following a four-day gain streak. The stock underperformed its sector and reached an intraday low, indicating mixed momentum. Over the past month, it has faced substantial challenges, contrasting sharply with broader market trends.

Orchid Pharma, a midcap pharmaceutical company, saw a significant decline on February 7, 2025, following a four-day gain streak. The stock underperformed its sector and reached an intraday low, indicating mixed momentum. Over the past month, it has faced substantial challenges, contrasting sharply with broader market trends.

Orchid Pharma, a midcap pharmaceutical company, saw a significant decline on February 7, 2025, following a four-day gain streak. The stock underperformed its sector and reached an intraday low, indicating mixed momentum. Over the past month, it has faced substantial challenges, contrasting sharply with broader market trends.

Orchid Pharma experienced significant trading activity on January 29, 2025, rebounding after four days of decline. The stock outperformed its sector and reached an intraday high, although it remains below several key moving averages. Over the past month, it has faced notable volatility compared to the broader market.

Orchid Pharma experienced significant trading activity on January 29, 2025, rebounding after four days of decline. The stock outperformed its sector and reached an intraday high, although it remains below several key moving averages. Over the past month, it has faced notable volatility compared to the broader market.

Orchid Pharma experienced significant trading activity on January 29, 2025, rebounding after four days of decline. The stock outperformed its sector and reached an intraday high, although it remains below several key moving averages. Over the past month, it has faced notable volatility compared to the broader market.

Orchid Pharma's stock has faced a significant decline, dropping for four consecutive days and totaling a 13.6% decrease. The stock opened lower today, reaching an intraday low and underperforming against its sector. It is trading below all key moving averages, reflecting ongoing bearish trends in the pharmaceuticals industry.